title: [Application of cationic propyl gallate as inducer of thrombocyte aggregation for evaluating the platelet function of platelet donors].
abstract: The purpose of study was to investigate the feasibility of the application of cationic propyl gallate (C-PG) as inducer of platelet aggregation for evaluating the platelet function of single-donor plateletpheresis and identifying the incidence of defective platelet function among donors. Experiments were as follows: 3 healthy volunteers' platelet aggregation induced by 100-300 micromol/L C-PG was determined by LG-PABER analyzer to observe the effect of C-PG concentration on platelet aggregation; 30 healthy volunteers' platelet aggregation before and 24 hours after administration of 200-400 mg acetylsalicylic acid (ASA) was examined after induction by 200 micromol/L C-PG for determining the cut-off value to discriminate platelet dysfunction donors; the platelet aggregation of 483 platelet donors was detected and the activated plasma clotting time (APCT) of donors who have deficiency in platelet aggregation was examined for investigating the incidence of defective platelet function among donors. The results showed that platelets were activated by C-PG induction in a dose dependent manner, when concentration of C-PG reached 200 micromol/L, the percentage of platelet aggregation was highest. It significantly decreased after 24 hours with ASA than that before the administration (P < 0.001), especially in 180 seconds induced by C-PG. If cut-off point was fixed on the platelet aggregation < 20% in 180 seconds, donors of platelet dysfunction can be selected effectively. 25 of defective platelet aggregation function among 483 donors were detected, and 11 out of 25 platelet dysfunction donors had the deficiency in procoagulant activity with prolonged APCT. It is concluded that C-PG as inducer of platelet aggregation is feasible to screen the platelet function of donors. Five percent of platelet donors has function defect examined by C-PG as inducer of platelet aggregation.
authors.affiliation: Jiangsu Province Blood Center, Nanjing 210042, China.
authors.forename: Da-Xiang
authors.initials: DX
authors.lastname: Sheng
authors.forename: Cheng-Yin
authors.initials: CY
authors.lastname: Huang
authors.forename: Guang-Yao
authors.initials: GY
authors.lastname: Shi
authors.forename: Xi-Lin
authors.initials: XL
authors.lastname: Ouyang
authors.forename: Li
authors.initials: L
authors.lastname: Cai
authors.forename: Jian-Yu
authors.initials: JY
authors.lastname: Xiao
authors.forename: Rong-Cai
authors.initials: RC
authors.lastname: Tang
mesh_terms: D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage*; D001782:Blood Donors; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D002412:Cations / Q000737:chemistry; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D010979:Platelet Function Tests; D017713:Platelet Transfusion; D011435:Propyl Gallate / Q000008:administration & dosage* / Q000737:chemistry; D014914:Whole Blood Coagulation Time
chemical_list: D000975:Antioxidants; D002412:Cations; D010975:Platelet Aggregation Inhibitors; D011435:Propyl Gallate; D001241:Aspirin